For severe alopecia areata, Zejing Pharmaceutical's JAK inhibitor initiates Phase 3 clinical trials

On June 2, the China Drug Clinical Trial Registration and Information Disclosure Platform showed that Zejing Pharmaceuticals launched a Phase 3 clinical trial of Jacketinib Hydrochloride Tablets for the treatment of severe alopecia areata
.

Alopecia areata is the second highest incidence of hair loss in the world.
There are approximately 147 million patients with alopecia areata in the world, and there are about 4 million patients in China
.
It is an autoimmune disease in which the immune system attacks the hair follicles, causing partial or complete hair loss on the scalp, face or other parts of the body
.
Alopecia areata symptoms often occur for the first time in childhood, and people of any age, gender, and race may suffer from alopecia areata
.

At present, the existing treatment drugs and steroids do not provide meaningful improvement for many patients with alopecia areata, and they urgently need an effective treatment plan
.
JAK inhibitors are considered to be the first to achieve a breakthrough in the treatment of alopecia areata, and they have become one of the popular drug candidates for the treatment of alopecia areata
.

Just in April of this year, Eli Lilly and Company and Incyte's JAK inhibitor baritinib achieved positive results in the second phase 3 clinical trial for the treatment of patients with severe alopecia areata.
It is planned to be in the second half of this year.
Submit a supplementary new drug application (sNDA) to the US FDA
.
In addition, ritlecitinib, a JAK3 inhibitor developed by Pfizer, has shown gratifying effects in the phase 2 clinical trial for the treatment of alopecia areata, and has been awarded "breakthrough therapy designation" by the FDA and the National Food and Drug Administration (NMPA)
.
In addition, a variety of JAK inhibitors are also used in clinical trials to treat alopecia areata, and Jacketinib is one of them
.

Public information shows that Jacketinib hydrochloride tablets are new small-molecule JAK kinase inhibitor drugs independently developed by Zejing Pharmaceuticals with independent intellectual property rights, and belong to a class 1 new drug
.
Jacketinib hydrochloride can inhibit the non-receptor tyrosine Janus related kinases JAK1, JAK2 and JAK3
.
It is reported that Jectinib hydrochloride can effectively inhibit the activation of the JAK signaling pathway and inhibit the phosphorylation of activator of transcription (STAT), thereby inhibiting the expression of downstream genes regulated by STAT
.

This time, Zejing Pharmaceutical initiated a multi-center, randomized, double-blind, placebo-controlled phase 3 clinical trial.
The main purpose is to confirm the effectiveness of Jacketinib hydrochloride tablets in the treatment of severe alopecia areata.
The secondary purpose is to observe hydrochloric acid.
The safety and pharmacokinetic characteristics of Jacketinib tablets in the treatment of severe alopecia areata
.
The research plan enrolls 354 people in China, and Dr.
Jianzhong Zhang, chief physician of Peking University People's Hospital, and Dr.
Qianjin Lu, chief physician of the Dermatology Hospital of the Chinese Academy of Medical Sciences, will serve as the main investigators
.

In addition to targeting alopecia areata, Zejing Pharmaceutical is also carrying out a number of clinical studies on Jacketinib hydrochloride tablets.
The indications include: myelofibrosis, idiopathic pulmonary fibrosis, ankylosing spondylitis, moderate to severe plaque psoriasis, Moderate to severe atopic dermatitis and so on
.
(Medicine Guanlan )

Note: The original text has been deleted

Reference materials:

[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
from http:// The results of the Phase II clinical study of Zektinib tablets in the treatment of intermediate and high-risk myelofibrosis by Zejing Pharmaceuticals were selected in EHA 2021.
Retrieved Apr 25, 2021, from http:// 25/214.
html